NCT02770014View on ClinicalTrials.gov

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 16, 2019

Study Completion Date

June 19, 2019

Conditions

Epidermal Growth Factor ReceptorNon-Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER